ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 54.34% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 36.97M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 36.97M.
Undervalued
The company’s latest PE is -18.57, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 15.83M shares, increasing 10.52% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 124.35K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.01.